Unmasking the Silent Glomus Tumor of the Index Finger – A Case Report and Literature Review

Clinical Phenotype as a Sentinel Marker for Severe Waardenburg-Shah Syndrome: A Case Report of Total Colonic Aganglionosis with a Fatal Outcome

Failed Thiamine Trial as a Diagnostic Pivot to Tuberculous Meningitis in Alcohol-Related Encephalopathy

Ewing Sarcoma of the Kidney: A Case Report

IntroductionAmong invasive fungal infections, mucormycosis is the third most common cause [1]. This life-threatening condition results from infections caused by Mucorales fungi and is associated withsignificant mortality rates in hospitalized patients [2]. Although these infections are rare, a rising number of instances are being reported in immunocompromised individuals. Major risk factors for mucormycosis include poorly controlled diabetes, prolonged high-dose glucocorticoid use, neutropenia, organ transplantation, iron overload, and, more recently, COVID-19 infection [3,4]. Mucorales infections can manifest in different ways, such as cutaneous and soft tissue infections, rhino-orbito-cerebral disease, pulmonary or gastrointestinal involvement, disseminated infection, and other rare presentations. Diagnosis relies on detecting distinctive, broad hyphae in tissue specimens or isolating the fungus through mycological culture. Delayed treatment significantly raises mortality [5,6,7]. Chronic HBV infection may lead to varying degrees of liver dysfunction and immune dysregulation, potentially increasing susceptibility to opportunistic pathogens [8,9]. In this report, we present a rare and clinically significant case of mucormycosis in a patient with chronic hepatitis B. Through this case, we aim to highlight the importance of maintaining a high index of suspicion for invasive fungal infections even in non-traditional hosts. To our knowledge, very few cases of mucormycosis associated with hepatitis B infection have been reported in the literature.

IntroductionRhinophyma represents a severe, disfiguring manifestation of phymatous rosacea, characterized by progressive glandular hypertrophy and fibroplasia of the nasal soft tissues [1]. Pathologically, it is defined by marked sebaceous hyperplasia, which can precipitate significant aesthetic distortion and, in advanced stages, functional airway obstruction [1, 2]. While primarily localized to the nose, phymatous changes can occasionally involve adjacent facial structures [3]. The clinical presentation varies in severity, a spectrum which often guides the therapeutic strategy [4].Although surgical excision is the definitive treatment for advanced rhinophyma, recurrence remains a formidable therapeutic challenge. Relapse is frequently attributed to the incomplete extirpation of deep-seated sebaceous follicular units that serve as a nidus for regrowth. The literature, however, offers limited guidance on optimal strategies for managing patients after multiple surgical failures. In this case, we present a rare case of triple-recurrent rhinophyma to illustrate the profound therapeutic challenges involved and to delineate the meticulous surgical principles essential for achieving a durable aesthetic and functional outcome in such recalcitrant scenarios.

A document by Fazeela Bibi. Click on the document to view its contents.

IntroductionCongenital Dyserythropoietic Anemia Type II (CDA-II) is a rare autosomal recessive disorder characterized by ineffective erythropoiesis, typically caused by biallelic mutations in the SEC23B gene [1]. This gene encodes a crucial component of the COPII coat protein complex responsible for intracellular protein transport [2]. Clinically, CDA-II presents with lifelong anemia of variable severity, jaundice, and hepatosplenomegaly [1]. However, arriving at a correct diagnosis is often challenging due to significant phenotypic heterogeneity and clinical overlap with more common hereditary anemias [3]. In regions where disorders like thalassemia are endemic, the similar presentation of chronic, transfusion-dependent anemia frequently leads to misdiagnosis, delaying appropriate management [4].This diagnostic delay can lead to severe and preventable long-term complications. Patients often develop significant iron overload, not only from repeated transfusions but also from increased intestinal absorption driven by the profound ineffective erythropoiesis. Other sequelae include growth retardation, gallstones, and, in resource-limited settings, transfusion-transmitted infections. While the morphological hallmark of CDA-II is the presence of binucleated erythroblasts in a hypercellular bone marrow, this finding is not entirely specific and modern diagnostic standards rely on molecular confirmation [5]. The transition from a morphology-based diagnosis to a genetically confirmed one is critical for guiding management and preventing irreversible organ damage.Here, we report the case of a 13-year-old girl from South Asia with a classic CDA-II phenotype whose diagnosis was delayed for years due to the regional prevalence of thalassemia. This case illustrates the severe morbidity that accumulates from a delayed diagnosis, including growth failure, extreme iron overload, and transfusion-acquired hepatitis C. It underscores the limitations of relying solely on morphological findings in a complex diagnostic landscape and highlights the critical need for increased awareness and access to definitive genetic testing in resource-constrained environments to improve patient outcomes.

IntroductionThe widespread use of high-resolution, cross-sectional imaging has led to a dramatic increase in the incidental detection of pancreatic cystic lesions (PCLs), confronting clinicians with a high-stakes diagnostic challenge [1]. The central task is to accurately risk-stratify these lesions, distinguishing benign, non-neoplastic entities from pancreatic cystic neoplasms (PCNs) that harbor malignant potential [2]. This distinction is critical, as misclassification can lead either to unnecessary, high-morbidity pancreatectomy for benign cysts or, conversely, a missed opportunity to resect a pre-malignant or early-stage malignant tumor [3].Among the most frequent and consequential diagnostic dilemmas is the differentiation between a pancreatic pseudocyst (PPC)—a non-neoplastic, encapsulated fluid collection arising from pancreatitis—and a mucinous cystic neoplasm (MCN). PPCs are the most common PCL, accounting for approximately 75% of cases, and are defined by a fibrous wall devoid of an epithelial lining [5]. In contrast, MCNs are true neoplasms characterized by mucin-producing epithelial cells and an underlying ovarian-like stroma, carrying a significant risk of malignant transformation that prompts recommendations for surgical resection [6]. Despite these distinct pathologies, their radiological features can overlap substantially; large or complex PPCs containing debris can mimic the septations, wall thickening, and internal complexity characteristic of an MCN, creating significant diagnostic ambiguity from imaging alone [5].When initial imaging is inconclusive, a multimodal diagnostic algorithm is essential [3]. Endoscopic ultrasound (EUS) with fine-needle aspiration (FNA) allows for high-resolution morphologic assessment and cyst fluid acquisition [7]. Subsequent analysis of the cyst fluid for tumor markers, such as carcinoembryonic antigen (CEA), and cytology provides critical data to resolve the differential [8]. While high levels of CEA are strongly suggestive of a mucinous lesion, elevated amylase points towards a pseudocyst, and cytology can confirm malignancy, each test has known limitations [8].However, extreme clinical presentations, such as a cyst of massive size, can heavily bias initial interpretation towards neoplasia, creating a significant diagnostic pitfall that may lead to premature closure. In this report, we present the case of a patient with a 1.85-liter pancreatic cyst whose immense size and complex features on imaging were highly suggestive of an MCN. We detail the systematic application of a multimodal diagnostic approach that successfully averted a misdiagnosis, underscoring the principle that even in the face of atypical features, a stepwise, evidence-based evaluation is paramount to ensure correct diagnosis and guide appropriate management.

IntroductionThe presence of a single abdominal wall hernia is a common surgical problem, but the synchronous presentation of multiple, distinct hernias in a single patient represents a significant diagnostic and therapeutic challenge [1]. Such cases may signal an underlying systemic predisposition to fascial weakness, a concept increasingly described as ”abdominal wall failure,” rather than a series of coincidental events [2]. There is substantial evidence that a deficiency in type 1 collagen, inadequate collagen cross-linking, or other connective tissue abnormalities may underpin the development of multiple hernias, creating a generalized vulnerability to herniation [2]. This perspective shifts the clinical paradigm from treating an isolated defect to managing a systemic condition with local manifestations.While reports of double or even triple hernias exist, they often involve bilateral presentations of a single type, such as inguinal hernias [3]. The combination of hernias across different anatomical zones—such as the groin, the umbilical region, and a prior surgical site—is less commonly documented and complicates surgical planning [4]. A key clinical pitfall is the presence of occult or ”hidden” hernias, where a larger, more symptomatic hernia obscures the detection of smaller, concurrent defects during physical examination [5]. Failure to identify all existing hernias preoperatively can lead to persistent patient symptoms, the need for repeat operations, and an increased risk of recurrence [6].Herein, we present the rare case of a 56-year-old male with three concurrent hernias: a right indirect inguinal hernia, an umbilical hernia, and an incisional hernia at the site of a previous appendectomy. This case highlights the critical importance of maintaining a high index of suspicion for multiple defects and underscores the utility of preoperative imaging for comprehensive surgical planning. Furthermore, we use this case to explore the potential for a unifying pathophysiological mechanism and discuss the surgical strategy for managing such complex abdominal wall disease in a single operative setting.

Metabolic Reset and Remodel: A Quantitative Analysis of the Two-Hit Pathway from DKA to Durable Remission in Ketosis-Prone Diabetes

IntroductionThe escalating use of high-resolution, cross-sectional abdominal imaging has led to a substantial increase in the detection of pancreatic cystic lesions (PCLs), which are estimated to be present in up to 45% of the general population [1]. This rising prevalence presents a formidable clinical challenge: differentiating the vast majority of indolent or benign cysts, such as serous cystadenomas (SCAs), from neoplasms with malignant potential, including intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) [1-3]. This challenge is most acute when diagnostic modalities provide conflicting data, creating a clinical dilemma between observation and high-morbidity surgery. Current management guidelines from major international societies therefore recommend a multimodal approach to risk stratification, integrating patient demographics, symptomology, and specific morphologic features on imaging to guide decisions between surveillance and surgical resection [1].Central to this diagnostic algorithm is the serum biomarker Carbohydrate Antigen 19-9 (CA 19-9), a well-established marker for pancreatic ductal adenocarcinoma where profoundly elevated levels often correlate with advanced disease [4]. While its utility is limited by elevations in benign obstructive pancreatobiliary conditions, levels exceeding 1000 U/mL are viewed as having a high specificity for pancreatobiliary malignancy and are rarely observed in the absence of malignancy [4]. Conversely, SCAs, which are benign in over 99% of cases, are characteristically associated with normal serum CA 19-9 levels [5]. In a multinational study of over 2600 patients with SCA, this serological quiescence was a consistent feature, reinforcing its role as a low-risk entity [6].This report details a rare case that directly challenges this established diagnostic paradigm, presenting a profound discordance between classic benign imaging and a malignant-range tumor marker. The purpose of this case is to document this instructive presentation, explore the potential biologic mechanisms underlying such a paradoxical finding, and underscore the limitations of relying on a single, discordant biomarker in the complex evaluation of PCLs.